Table of Contents
Securities and Exchange Commission
Washington, D.C. 20549
Form 6-K
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d/16 of
the Securities Exchange Act of 1934
November 2021
AEGON N.V.
Aegonplein 50
2591 TV THE HAGUE
The Netherlands
Table of Contents
Aegon’s condensed consolidated interim financial statements for the periods ended September 30, 2021, dated November 11, 2021, are included as appendix and incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AEGON N.V. | ||||||
(Registrant) | ||||||
Date: November 12, 2021 | By | /s/ J.H.P.M. van Rossum | ||||
J.H.P.M. van Rossum | ||||||
Executive Vice President and Head of Corporate Financial Center |
Table of Contents
AEGON
Condensed consolidated interim financial statements
for the period ended September 30, 2021
The Hague, November 11, 2011
Helping people achieve a lifetime of financial security
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
2 | ||||
3 | ||||
4 | ||||
5 | ||||
6 | ||||
Notes to the condensed consolidated interim financial statements | 7 |
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
1 Please refer to the note on Share Capital for further details
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
1 Please refer to the note on Share Capital for a breakdown.
2 Issued capital and reserves attributable to owners of Aegon N.V.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
1 Trust pass-through securities
2 Included in net increase / (decrease)in cash and cash equivalents are interest received EUR 3,910 million (2020: EUR 3,777 million) dividends received EUR 1,267 million (2020: EUR 1,407 million) and interest paid EUR 75 million (2020: EUR 196 million). All included in operating activities except for dividend received from joint ventures and associates EUR 80 million (2020: EUR 85 million).
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Notes to the Condensed consolidated interim financial statements
Amounts are in EUR millions, unless otherwise stated.
Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.
Aegon N.V. (or ‘the Company’) and its subsidiaries (‘Aegon’ or ‘the Group’) have life insurance and pensions operations and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Aegon focuses on three core markets (the United States, the Netherlands, and the United Kingdom), three growth markets (Spain & Portugal, China, and Brazil) and one global asset manager. Headquarters are located in The Hague, the Netherlands. The Group employs over 22,000 people worldwide.
1. Basis of presentation
The condensed consolidated interim financial statements as at, and for the nine-month period ended, September 30, 2021 (‘YTD 2021’) and the third quarter 2021 (‘3Q 2021’), have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’, as adopted by the European Union (hereafter ‘IFRS-EU’). They do not include all of the information required for a full set of financial statements prepared in accordance with IFRS-EU and should therefore be read together with the 2020 consolidated financial statements of Aegon N.V. as included in Aegon’s Integrated Annual Report for 2020. Aegon’s Integrated Annual Report for 2020 is available on its website (aegon.com).
The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value. The condensed consolidated interim financial statements as at, and for the period ended, September 30, 2021, were approved by the Supervisory Board on November 10, 2021.
The condensed consolidated interim financial statements are presented in euro (EUR) and all values are rounded to the nearest million unless otherwise stated. The consequence is that the rounded amounts may not add up to the rounded total in all cases.
The published figures in these condensed consolidated interim financial statements are unaudited.
2. Significant accounting policies
All accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2020 consolidated financial statements. New IFRS accounting standards and amendments that became effective on or after January 1, 2021 had no material impact on Aegon’s financial position or condensed consolidated interim financial statements (refer to paragraph 2.1).
2.1. New IFRS accounting standards effective from 2021
In 2021, the following amendments to existing standards issued by the IASB became effective:
◆ | Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16); |
◆ | Extension of the Temporary Exemption from Applying IFRS 9 (Amendments to IFRS 4 Insurance Contracts); and |
◆ | COVID-19-Related Rent Concessions beyond 30 June 2021 (Amendment to IFRS 16). |
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
2.2. Future adoption of new IFRS-EU accounting standards and amendments
For a complete overview of IFRS standards and amendments issued before January 1, 2021, which will be applied in future years and were not early adopted by the Group, please refer to Aegon’s Integrated Annual Report for 2020.
After January 1, 2021, the IASB issued the following amendments:
◆ | Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2); |
◆ | Definition of Accounting Estimates (Amendments to IAS 8); and |
◆ | Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12). |
These amendments were not early adopted by Aegon and are not expected to have significant impact on Aegon’s financial position or condensed consolidated interim financial statements.
2.3. Judgments and critical accounting estimates
Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. These estimates are inherently subject to change and actual results could differ from those estimates.
Uncertainty resulting from COVID-19
In the first nine-month period of 2021 the COVID-19 pandemic continued to cause significant disruption to business, markets, and the industry. Progress on vaccinations has reduced the spread of COVID-19 and will likely continue to reduce the effects of the public health crisis on the economy. However, the pace of vaccinations has slowed down, and new strains of the virus and reduced availability of healthcare remain risks. Equity markets in Aegon’s three main markets increased in the first nine months of 2021 to grow following the drop of equity markets in the first half of 2020. Although interest rates remain low, they are well above lower levels of interest rates observed in early 2020.
In the first nine-month period of 2021, Aegon’s operating result in the Americas was impacted by EUR 259 million of adverse mortality in Life, of which EUR 171 million (first nine-month period of 2020: EUR 81 million) of claims are directly attributable to COVID-19 as the cause of death. This was offset by favorable morbidity experience in Accident & Health and is mostly related to Long-Term Care insurance with higher claims terminations due to higher mortality and discharges from care facilities. In 3Q 2021, Aegon continue to observe positive morbidity in Long-Term Care, but less favorable when compared to prior year. In 3Q 2021, Aegon started to release a portion of the Long-Term Care incurred but not reported (IBNR) reserve established during the peak of the pandemic.
In the first nine-month period of 2021 the total impairment charges amounted to EUR 15 million, compared to EUR 283 million in the first nine-month period of 2020. In 2020, impairment losses were significantly higher than in previous reporting periods and were the result of the uncertainty in the market and adverse impact of COVID-19. Aegon recorded impairments primarily in the energy, energy maintenance technologies, and communications sectors.
Aegon Group’s Solvency II capital position remained at a strong level increasing from 196% per December 31, 2020, to 209% per September 30, 2021.
Aegon continues to monitor the relevant market and the economic factors to proactively manage the associated risks. Management believes that the most significant risks are related to financial markets (particularly credit, equity, and interest rates risks) and underwriting risks (particularly related to mortality, morbidity, and policyholder behavior).
Actuarial and economic assumptions
In the first nine-month period of 2021, Aegon implemented actuarial assumption and model updates resulting in a net EUR 46 million charge to income before tax (first nine-month period of 2020: EUR 504 million charge). This is mainly related to Aegon’s businesses in the Americas and the Netherlands.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
The indexation assumption for a specific pensions portfolio linked to Dutch industry pension funds has been updated after a sharp rise of the price inflation curve. Instead of a historical analysis, the substantiation of the updated indexation assumption will be based on a new forward-looking method that also takes into account the drivers (coverage ratio, asset mix, expected returns) for indexation pay-out by industry pension funds. The updated indexation assumption resulted in a lower market value liability of EUR 75 million. The release of the liability has been recorded as part of Benefits and expenses and in Other income / (charges) for segment reporting purposes.
In addition, the Variable Annuities Guaranteed Lifetime Withdrawal Benefit (VA GLWB) surrender floor in the Americas is updated from 2% to 1.5% to reflect latest portfolio and industry experience. The impact of this assumption change resulted in an EUR 123 million charge to income before tax and has been recorded as part of Benefits and expenses and in Other income / (charges) for segment reporting purposes.
Sensitivities
Sensitivity on variable annuities and variable life insurance products in the United States
Sensitivities of Aegon’s variable annuities and variable life insurance products in the United States on expected long-term equity growth rate have not significantly changed compared to the sensitivities as reported in the Aegon’s 2020 Integrated Annual Report, except for sensitivities to long-term equity growth rate.
A decrease of 1% in the expected long-term equity growth rate with regard to Aegon’s variable annuities and variable life insurance products in the United States would result in a decrease in DPAC and VOBA balances and reserve strengthening of approximately EUR 98 million (December 31, 2020: EUR 108 million). The DPAC and VOBA balances for these products in the United States amounted to EUR 2.1 billion (December 31, 2020: EUR 2.4 billion).
Sensitivity on liability adequacy test (LAT) in the Netherlands
At September 30, 2021, the liability adequacy test (LAT) of Aegon the Netherlands remains in a deficit position. The LAT assesses the adequacy of the insurance liabilities by comparing them to their fair value. Aegon the Netherlands adjusts the outcome of the LAT for certain unrealized gains in the bond portfolio and certain differences between the fair value and the book value of assets measured at amortized cost, mainly residential mortgages. Please also refer to Note 2.19f Liability adequacy testing of Aegon’s 2020 Integrated Annual Report for further details on the accounting policy.
The LAT deficit per September 30, 2021 in Aegon the Netherlands amounted to EUR 4.7 billion (December 31, 2020: EUR 7.0 billion), which was partially offset by the shadow loss recognition of EUR 3.2 billion (December 31, 2020: EUR 4.5 billion), resulting in a net deficit of EUR 1.5 billion (December 31, 2020: EUR 2.5 billion). The improvement of the LAT deficit amounting to EUR 1.0 billion is driven by market movements (mainly increased interest rates and tightened credit spreads) and is recorded in the income statement as part of benefits and expenses for the nine-month period ended September 30, 2021.
Sensitivities of Aegon the Netherlands on bond credit spread, mortgage spread and liquidity premium assumptions to assess the impact on the LAT have not significantly changed compared to the sensitivities as reported in the 2020 Aegon’s Integrated Annual Report, except for sensitivities to interest rate. An increase of 100 bps in interest rate would result in a decrease in LAT deficit of EUR 3.2 billion (December 31, 2020: EUR 3.9 billion). A decrease of 100 bps would result in an increase in LAT deficit of approximately EUR 4.2 billion (December 31, 2020: EUR 5.2 billion).
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
2.4. Other
Taxes
Taxes on income for the nine-month period ended September 30, 2021, are calculated using the tax rate that is estimated to be applicable to earnings for the full year.
Exchange rates
Assets and liabilities of foreign operations are translated to the presentation currency at the closing rates on the reporting date. Income, expenses and capital transactions (such as dividends) are translated at average exchange rates or at the prevailing rates on the transaction date, if more appropriate. The following exchange rates (most important rates) are applied for the condensed consolidated interim financial statements:
Closing exchange rates
USD | GBP | |||||||
September 30, 2021 | 1 | EUR | 1.1590 | 0.8595 | ||||
December 31, 2020 | 1 | EUR | 1.2236 | 0.8951 | ||||
Weighted average exchange rates
| ||||||||
USD | GBP | |||||||
Nine months ended September 30, 2021 | 1 | EUR | 1.1964 | 0.8637 | ||||
Nine months ended September 30, 2020 | 1 | EUR | 1.1245 | 0.8848 |
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
3. Segment information
3.1. Change in name convention of performance measure
As disclosed in the 1Q 2021 interim financial statements, Aegon has changed the name convention of its primary performance measure to improve alignment with industry practice. As of 2021, Aegon will no longer refer to underlying earnings before tax for segment reporting purposes, instead Aegon will refer to Operating result. Furthermore, Aegon introduced a new grouping of non-operating result which is the sum of Fair value items, Realized gains / (losses) on investments, and Net impairments. Other income / charges remains a separate category outside of Aegon’s operating result.
3.2. Change in measurement of performance measure
In addition, Aegon has changed the measurement of its operating result from January 1, 2021. The following changes have been made:
1. | The running cost of the US macro hedge related to the variable annuity portfolio are recorded within Operating result instead of in Fair value items. Management views this as a better reflection of Aegon’s operating performance and will make Aegon’s operating result more relevant. |
2. | The periodic intangibles unlocking in the US Life and TLB business is recorded in Fair value items, instead of Operating result, to improve the insight in Aegon’s recurring operating result. |
3. | Results from run-off businesses in the US are part of Aegon’s operating result. The results of run-off businesses were previously recorded outside of Aegon’s operating result. Based on management actions executed in prior years the importance of run-off businesses has diminished and continuing to report this as a separate line item is considered no longer relevant. |
4. | Following the announcement to sell Aegon’s operations in CEE, results from these businesses, previously reported in operating result, are prospectively recorded within Other income / charges. |
For segment reporting purposes, the impact of these changes in measurement compared to the first nine months of 2020 was an increase in Aegon’s consolidated operating result of EUR 16 million, as certain losses are no longer reported in Fair value items (EUR 30 million) and results of Run-off businesses are no longer separately reported (EUR 13 million gain). There is no impact on Aegon’s net result, shareholders’ equity, dividend per share, or any of the main schedules included in Aegon’s condensed consolidated interim financial statements, in any of the reporting periods. Comparative numbers have been restated in Aegon’s segment reporting note, enabling a like for like comparison, with the exception of the reclassification of the results from Aegon’s operations in CEE to Other income / charges which is applied prospectively.
Unaudited
|
|
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
3.3. Segment results
The following table presents Aegon’s segment results.
EUR millions | Americas | The Netherlands | United Kingdom | International | Asset management | Holdings and other activities | Eliminations | Segment total |
Joint ventures and associates eliminations | Consolidated | ||||||||||||||||||||||||||||||
Three months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
Operating result geographically | 160 | 190 | 51 | 36 | 58 | (52 | ) | (1 | ) | 443 | 22 | 465 | ||||||||||||||||||||||||||||
Fair value items | 126 | (261 | ) | 13 | (4 | ) | - | (4 | ) | - | (130 | ) | (38 | ) | (167 | ) | ||||||||||||||||||||||||
Realized gains / (losses) on investments | 56 | 72 | - | 4 | - | - | - | 132 | (2 | ) | 130 | |||||||||||||||||||||||||||||
Impairment charges | (9 | ) | (3 | ) | - | - | - | (4 | ) | - | (16 | ) | (1 | ) | (17 | ) | ||||||||||||||||||||||||
Impairment reversals | 3 | 19 | - | - | - | - | - | 22 | - | 22 | ||||||||||||||||||||||||||||||
Non-operating items | 177 | (173 | ) | 13 | - | - | (8 | ) | - | 9 | (40 | ) | (31 | ) | ||||||||||||||||||||||||||
Other income / (charges) | (539 | ) | (2 | ) | (2 | ) | 11 | (6 | ) | (21 | ) | - | (559 | ) | - | (559 | ) | |||||||||||||||||||||||
Result before tax | (202 | ) | 15 | 62 | 48 | 52 | (81 | ) | (1 | ) | (107 | ) | (18 | ) | (124 | ) | ||||||||||||||||||||||||
Income tax (expense) / benefit | 72 | (6 | ) | (13 | ) | (12 | ) | (15 | ) | 20 | - | 47 | 18 | 65 | ||||||||||||||||||||||||||
Net result | (130 | ) | 10 | 49 | 37 | 36 | (61 | ) | (1 | ) | (60 | ) | - | (60 | ) | |||||||||||||||||||||||||
Inter-segment operating result after tax | (5 | ) | (23 | ) | (26 | ) | (8 | ) | 49 | 13 | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||||||||||||
Life insurance gross premiums | 1,780 | 304 | 1,042 | 257 | - | - | - | 3,384 | (187 | ) | 3,196 | |||||||||||||||||||||||||||||
Accident and health insurance | 315 | 39 | - | 21 | - | - | - | 375 | (11 | ) | 364 | |||||||||||||||||||||||||||||
Property & casualty insurance | - | 34 | - | 107 | - | - | - | 141 | (39 | ) | 101 | |||||||||||||||||||||||||||||
Total gross premiums | 2,095 | 377 | 1,042 | 385 | - | - | - | 3,899 | (238 | ) | 3,662 | |||||||||||||||||||||||||||||
Investment income | 745 | 485 | 141 | 90 | 3 | 62 | (67 | ) | 1,459 | (19 | ) | 1,440 | ||||||||||||||||||||||||||||
Fee and commission income | 481 | 83 | 60 | 15 | 183 | - | (46 | ) | 775 | (67 | ) | 708 | ||||||||||||||||||||||||||||
Other revenues | 3 | - | - | 1 | 1 | 6 | - | 11 | (4 | ) | 6 | |||||||||||||||||||||||||||||
Total revenues | 3,325 | 944 | 1,243 | 491 | 187 | 67 | (113 | ) | 6,144 | (328 | ) | 5,816 | ||||||||||||||||||||||||||||
Inter-segment revenues | - | 4 | - | - | 46 | 63 | ||||||||||||||||||||||||||||||||||
EUR millions | Americas | The Netherlands | United Kingdom | International | Asset management | Holdings and other activities | Eliminations | Segment total |
Joint ventures and associates eliminations | Consolidated | ||||||||||||||||||||||||||||||
Three months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
Operating result geographically | 272 | 176 | 31 | 44 | 58 | (54 | ) | 1 | 526 | (1 | ) | 526 | ||||||||||||||||||||||||||||
Fair value items | 156 | (706 | ) | (36 | ) | - | - | 8 | - | (577 | ) | (17 | ) | (594 | ) | |||||||||||||||||||||||||
Realized gains / (losses) on investments | 20 | 7 | - | 31 | - | - | - | 59 | (3 | ) | 56 | |||||||||||||||||||||||||||||
Impairment charges | (30 | ) | 12 | - | - | - | (6 | ) | - | (25 | ) | - | (25 | ) | ||||||||||||||||||||||||||
Impairment reversals | 4 | - | - | - | - | - | - | 5 | - | 5 | ||||||||||||||||||||||||||||||
Non-operating items | 151 | (686 | ) | (36 | ) | 31 | - | 2 | - | (538 | ) | (20 | ) | (558 | ) | |||||||||||||||||||||||||
Other income / (charges) | (110 | ) | (362 | ) | (12 | ) | (10 | ) | (1 | ) | (41 | ) | - | (536 | ) | - | (536 | ) | ||||||||||||||||||||||
Result before tax | 312 | (873 | ) | (17 | ) | 65 | 57 | (93 | ) | 1 | (547 | ) | (21 | ) | (568 | ) | ||||||||||||||||||||||||
Income tax (expense) / benefit | (45 | ) | 194 | 5 | (19 | ) | (16 | ) | 11 | - | 129 | 21 | 150 | |||||||||||||||||||||||||||
Net result | 267 | (679 | ) | (12 | ) | 46 | 41 | (82 | ) | 1 | (418 | ) | - | (418 | ) | |||||||||||||||||||||||||
Inter-segment operating result after tax | (12 | ) | (21 | ) | (20 | ) | (6 | ) | 44 | 15 | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||||||||||||
Life insurance gross premiums | 1,723 | 320 | 1,000 | 228 | - | 1 | (1 | ) | 3,271 | (152 | ) | 3,120 | ||||||||||||||||||||||||||||
Accident and health insurance | 332 | 44 | 6 | 23 | - | - | - | 405 | (11 | ) | 394 | |||||||||||||||||||||||||||||
Property & casualty insurance | - | 32 | - | 96 | - | - | - | 128 | (31 | ) | 97 | |||||||||||||||||||||||||||||
Total gross premiums | 2,054 | 397 | 1,006 | 346 | - | 1 | (1 | ) | 3,804 | (194 | ) | 3,610 | ||||||||||||||||||||||||||||
Investment income | 722 | 522 | 187 | 90 | 2 | 64 | (71 | ) | 1,515 | (17 | ) | 1,498 | ||||||||||||||||||||||||||||
Fee and commission income | 421 | 62 | 46 | 12 | 218 | - | (44 | ) | 714 | (113 | ) | 601 | ||||||||||||||||||||||||||||
Other revenues | 3 | - | - | - | - | 1 | - | 4 | (3 | ) | 1 | |||||||||||||||||||||||||||||
Total revenues | 3,199 | 981 | 1,239 | 448 | 220 | 65 | (116 | ) | 6,037 | (327 | ) | 5,710 | ||||||||||||||||||||||||||||
Inter-segment revenues | - | 6 | - | - | 44 | 66 |
Unaudited
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
EUR millions | Americas | The Netherlands | United Kingdom | International | Asset management | Holdings and other activities | Eliminations | Segment total |
Joint ventures and associates eliminations | Consolidated | ||||||||||||||||||||||||||||||
Nine months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
Operating result geographically | 605 | 560 | 135 | 98 | 204 | (164 | ) | (1 | ) | 1,436 | (11 | ) | 1,425 | |||||||||||||||||||||||||||
Fair value items | 454 | (81 | ) | (53 | ) | (7 | ) | (1 | ) | 27 | 1 | 341 | (56 | ) | 285 | |||||||||||||||||||||||||
Realized gains / (losses) on investments | 227 | 88 | - | 7 | 2 | 1 | - | 325 | (7 | ) | 318 | |||||||||||||||||||||||||||||
Impairment charges | (16 | ) | (5 | ) | - | - | - | (11 | ) | - | (32 | ) | (1 | ) | (32 | ) | ||||||||||||||||||||||||
Impairment reversals | 27 | 33 | - | 1 | - | 8 | - | 68 | - | 68 | ||||||||||||||||||||||||||||||
Non-operating items | 692 | 35 | (53 | ) | - | 1 | 26 | 1 | 703 | (63 | ) | 640 | ||||||||||||||||||||||||||||
Other income / (charges) | (757 | ) | 124 | 4 | 40 | (12 | ) | (110 | ) | - | (710 | ) | 12 | (698 | ) | |||||||||||||||||||||||||
Result before tax | 540 | 719 | 86 | 139 | 192 | (247 | ) | - | 1,429 | (62 | ) | 1,367 | ||||||||||||||||||||||||||||
Income tax (expense) / benefit | (39 | ) | (178 | ) | (2 | ) | (30 | ) | (59 | ) | 53 | - | (254 | ) | 62 | (192 | ) | |||||||||||||||||||||||
Net result | 500 | 541 | 84 | 110 | 134 | (194 | ) | - | 1,175 | - | 1,175 | |||||||||||||||||||||||||||||
Inter-segment operating result after tax | (17 | ) | (69 | ) | (71 | ) | (25 | ) | 142 | 39 | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||||||||||||
Life insurance gross premiums | 5,259 | 1,011 | 3,426 | 893 | - | - | - | 10,589 | (625 | ) | 9,964 | |||||||||||||||||||||||||||||
Accident and health insurance | 935 | 220 | 3 | 161 | - | - | - | 1,319 | (56 | ) | 1,263 | |||||||||||||||||||||||||||||
Property & casualty insurance | - | 102 | - | 322 | - | - | - | 424 | (123 | ) | 301 | |||||||||||||||||||||||||||||
Total gross premiums | 6,194 | 1,333 | 3,429 | 1,376 | - | - | - | 12,332 | (803 | ) | 11,529 | |||||||||||||||||||||||||||||
Investment income | 2,154 | 1,510 | 1,304 | 266 | 8 | 181 | (195 | ) | 5,228 | (54 | ) | 5,174 | ||||||||||||||||||||||||||||
Fee and commission income | 1,400 | 223 | 162 | 43 | 606 | - | (135 | ) | 2,299 | (263 | ) | 2,036 | ||||||||||||||||||||||||||||
Other revenues | 8 | - | - | 2 | 2 | 9 | - | 21 | (10 | ) | 10 | |||||||||||||||||||||||||||||
Total revenues | 9,756 | 3,066 | 4,896 | 1,686 | 616 | 190 | (330 | ) | 19,880 | (1,131 | ) | 18,749 | ||||||||||||||||||||||||||||
Inter-segment revenues | 1 | 10 | - | - | 135 | 185 | ||||||||||||||||||||||||||||||||||
EUR millions | Americas | The Netherlands | United Kingdom | International | Asset management | Holdings and other activities | Eliminations | Segment total |
Joint ventures and associates eliminations | Consolidated | ||||||||||||||||||||||||||||||
Nine months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
Operating result geographically | 533 | 497 | 112 | 126 | 128 | (167 | ) | 2 | 1,231 | 9 | 1,240 | |||||||||||||||||||||||||||||
Fair value items | (598 | ) | 674 | 53 | (8 | ) | (7 | ) | (12 | ) | - | 102 | (47 | ) | 55 | |||||||||||||||||||||||||
Realized gains / (losses) on investments | 25 | 10 | - | 39 | 1 | - | - | 75 | (8 | ) | 67 | |||||||||||||||||||||||||||||
Impairment charges | (164 | ) | (54 | ) | - | (5 | ) | - | (10 | ) | - | (233 | ) | - | (233 | ) | ||||||||||||||||||||||||
Impairment reversals | 19 | 1 | - | - | - | - | - | 20 | - | 20 | ||||||||||||||||||||||||||||||
Non-operating items | (717 | ) | 630 | 53 | 26 | (6 | ) | (22 | ) | - | (36 | ) | (55 | ) | (91 | ) | ||||||||||||||||||||||||
Other income / (charges) | (1,048 | ) | (410 | ) | (65 | ) | 15 | (1 | ) | (97 | ) | - | (1,607 | ) | 1 | (1,606 | ) | |||||||||||||||||||||||
Result before tax | (1,233 | ) | 717 | 100 | 167 | 121 | (286 | ) | 2 | (413 | ) | (45 | ) | (457 | ) | |||||||||||||||||||||||||
Income tax (expense) / benefit | 335 | (121 | ) | 2 | (30 | ) | (34 | ) | 45 | - | 197 | 45 | 242 | |||||||||||||||||||||||||||
Net result | (898 | ) | 595 | 103 | 137 | 87 | (241 | ) | 2 | (216 | ) | - | (216 | ) | ||||||||||||||||||||||||||
Inter-segment operating result after tax | (31 | ) | (66 | ) | (65 | ) | (24 | ) | 136 | 50 | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||||||||||||
Life insurance gross premiums | 5,340 | 1,298 | 3,735 | 839 | - | 4 | (3 | ) | 11,213 | (567 | ) | 10,646 | ||||||||||||||||||||||||||||
Accident and health insurance | 1,059 | 213 | 19 | 173 | - | - | - | 1,465 | (48 | ) | 1,416 | |||||||||||||||||||||||||||||
Property & casualty insurance | - | 98 | - | 290 | - | - | - | 388 | (96 | ) | 292 | |||||||||||||||||||||||||||||
Total gross premiums | 6,400 | 1,609 | 3,755 | 1,302 | - | 4 | (3 | ) | 13,066 | (711 | ) | 12,354 | ||||||||||||||||||||||||||||
Investment income | 2,283 | 1,585 | 1,446 | 276 | 5 | 193 | (210 | ) | 5,578 | (46 | ) | 5,532 | ||||||||||||||||||||||||||||
Fee and commission income | 1,217 | 187 | 143 | 37 | 554 | - | (133 | ) | 2,005 | (234 | ) | 1,771 | ||||||||||||||||||||||||||||
Other revenues | 7 | - | - | 1 | 1 | 3 | - | 12 | (9 | ) | 3 | |||||||||||||||||||||||||||||
Total revenues | 9,907 | 3,381 | 5,344 | 1,616 | 560 | 200 | (347 | ) | 20,661 | (1,000 | ) | 19,661 | ||||||||||||||||||||||||||||
Inter-segment revenues | 1 | 15 | - | - | 133 | 198 |
Aegon’s segment information is prepared by consolidating on a proportionate basis Aegon’s joint ventures and associated companies.
The Americas recorded other charges of EUR 470 million driven by expanding the Variable Annuity dynamic hedging program (EUR 361 million) and executing the lump-sum buy-out program (EUR 109 million). Refer to note 7 Benefits and expenses for further details.
Unaudited
|
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
3.4. Investments
Amounts included in the tables on investments are presented on an IFRS-EU basis, which means that investments in joint ventures and associates are not consolidated on a proportionate basis. Instead, these investments are included on a single line using the equity method of accounting.
EUR Millions | Americas | The Netherlands | United Kingdom | International | Asset Management | Holding and other activities | Eliminations | Total | ||||||||||||||||||||||||
September 30, 2021 | ||||||||||||||||||||||||||||||||
Investments | ||||||||||||||||||||||||||||||||
Shares | 476 | 1,338 | 30 | 74 | - | 3 | - | 1,920 | ||||||||||||||||||||||||
Debt securities | 61,400 | 26,750 | 1,163 | 8,093 | 9 | - | - | 97,415 | ||||||||||||||||||||||||
Loans | 11,076 | 35,748 | - | 108 | - | 40 | - | 46,972 | ||||||||||||||||||||||||
Other financial assets | 8,422 | 85 | 776 | 196 | 232 | - | - | 9,711 | ||||||||||||||||||||||||
Investments in real estate | 34 | 2,450 | - | 16 | - | - | - | 2,500 | ||||||||||||||||||||||||
Investments general account | 81,407 | 66,371 | 1,970 | 8,488 | 241 | 43 | - | 158,519 | ||||||||||||||||||||||||
Shares | - | 8,616 | 19,110 | 241 | - | - | (4 | ) | 27,963 | |||||||||||||||||||||||
Debt securities | - | 11,927 | 7,535 | 136 | - | - | - | 19,598 | ||||||||||||||||||||||||
Unconsolidated investment funds | 111,344 | 711 | 70,285 | 610 | - | - | - | 182,950 | ||||||||||||||||||||||||
Other financial assets | - | 4,341 | 5,287 | 3 | - | - | - | 9,631 | ||||||||||||||||||||||||
Investments in real estate | - | - | 490 | - | - | - | - | 490 | ||||||||||||||||||||||||
Investments for account of policyholders | 111,344 | 25,595 | 102,708 | 989 | - | - | (4 | ) | 240,632 | |||||||||||||||||||||||
Investments on balance sheet | 192,751 | 91,966 | 104,677 | 9,477 | 241 | 43 | (4 | ) | 399,151 | |||||||||||||||||||||||
Off balance sheet investments third parties | 233,022 | 7,104 | 134,009 | 2,215 | 203,292 | - | - | 579,642 | ||||||||||||||||||||||||
Total revenue generating investments | 425,773 | 99,070 | �� | 238,686 | 11,692 | 203,533 | 43 | (4 | ) | 978,792 | ||||||||||||||||||||||
Investments | ||||||||||||||||||||||||||||||||
Available-for-sale | 66,681 | 24,912 | 1,417 | 8,353 | 213 | - | - | 101,576 | ||||||||||||||||||||||||
Loans | 11,076 | 35,748 | - | 108 | - | 40 | - | 46,972 | ||||||||||||||||||||||||
Financial assets at fair value through profit or loss | 114,960 | 28,856 | 102,771 | 1,000 | 28 | 3 | (4 | ) | 247,613 | |||||||||||||||||||||||
Investments in real estate | 34 | 2,450 | 490 | 16 | - | - | - | 2,989 | ||||||||||||||||||||||||
Total investments on balance sheet | 192,751 | 91,966 | 104,677 | 9,477 | 241 | 43 | (4 | ) | 399,151 | |||||||||||||||||||||||
Investments in joint ventures | 58 | 330 | - | 927 | 334 | 40 | - | 1,689 | ||||||||||||||||||||||||
Investments in associates | - | 1,046 | 8 | 22 | 149 | 21 | (14 | ) | 1,232 | |||||||||||||||||||||||
Other assets | 35,654 | 14,747 | 4,813 | 2,679 | 405 | 26,344 | (27,031 | ) | 57,611 | |||||||||||||||||||||||
Consolidated total assets | 228,463 | 108,088 | 109,498 | 13,105 | 1,130 | 26,448 | (27,049 | ) | 459,684 | |||||||||||||||||||||||
EUR Millions | Americas | The Netherlands | United Kingdom | International | Asset Management | Holding and other activities | Eliminations | Total | ||||||||||||||||||||||||
December 31, 2020 | ||||||||||||||||||||||||||||||||
Investments | ||||||||||||||||||||||||||||||||
Shares | 442 | 1,376 | 34 | 74 | 9 | 44 | - | 1,979 | ||||||||||||||||||||||||
Debt securities | 59,419 | 30,880 | 1,077 | 7,926 | 48 | 1 | - | 99,350 | ||||||||||||||||||||||||
Loans | 10,477 | 34,936 | - | 120 | - | 40 | - | 45,573 | ||||||||||||||||||||||||
Other financial assets | 7,056 | 91 | 883 | 102 | 152 | 23 | - | 8,308 | ||||||||||||||||||||||||
Investments in real estate | 37 | 2,331 | - | 16 | - | - | - | 2,385 | ||||||||||||||||||||||||
Investments general account | 77,431 | 69,615 | 1,994 | 8,238 | 208 | 108 | - | 157,595 | ||||||||||||||||||||||||
Shares | - | 8,227 | 16,877 | 187 | - | - | (3 | ) | 25,288 | |||||||||||||||||||||||
Debt securities | - | 12,150 | 7,579 | 156 | - | - | - | 19,885 | ||||||||||||||||||||||||
Unconsolidated investment funds | 104,374 | 706 | 63,084 | 613 | - | - | - | 168,777 | ||||||||||||||||||||||||
Other financial assets | - | 4,520 | 5,232 | 3 | - | - | - | 9,755 | ||||||||||||||||||||||||
Investments in real estate | - | - | 467 | - | - | - | - | 467 | ||||||||||||||||||||||||
Investments for account of policyholders | 104,374 | 25,603 | 93,240 | 959 | - | - | (3 | ) | 224,172 | |||||||||||||||||||||||
Investments on balance sheet | 181,805 | 95,218 | 95,234 | 9,197 | 208 | 108 | (3 | ) | 381,767 | |||||||||||||||||||||||
Off balance sheet investments third parties | 215,216 | 6,144 | 119,347 | 6,752 | 192,098 | - | (336 | ) | 539,220 | |||||||||||||||||||||||
Total revenue generating investments | 397,021 | 101,362 | 214,580 | 15,948 | 192,307 | 108 | (339 | ) | 920,987 | |||||||||||||||||||||||
Investments | ||||||||||||||||||||||||||||||||
Available-for-sale | 63,864 | 25,972 | 1,494 | 8,088 | 134 | 28 | - | 99,580 | ||||||||||||||||||||||||
Loans | 10,477 | 34,936 | - | 120 | - | 40 | - | 45,573 | ||||||||||||||||||||||||
Financial assets at fair value through profit or loss | 107,427 | 31,979 | 93,272 | 973 | 74 | 40 | (3 | ) | 233,762 | |||||||||||||||||||||||
Investments in real estate | 37 | 2,331 | 467 | 16 | - | - | - | 2,853 | ||||||||||||||||||||||||
Total investments on balance sheet | 181,805 | 95,218 | 95,234 | 9,197 | 208 | 108 | (3 | ) | 381,767 | |||||||||||||||||||||||
Investments in joint ventures | - | 327 | - | 846 | 204 | - | - | 1,376 | ||||||||||||||||||||||||
Investments in associates | 60 | 1,004 | 8 | 35 | 151 | 21 | (15 | ) | 1,264 | |||||||||||||||||||||||
Other assets | 35,010 | 19,467 | 3,740 | 2,405 | 545 | 32,695 | (33,400 | ) | 60,461 | |||||||||||||||||||||||
Consolidated total assets | 216,875 | 116,016 | 98,982 | 12,482 | 1,109 | 32,824 | (33,419 | ) | 444,868 |
Unaudited
|
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
4. Premium income and premiums paid to reinsurers
EUR millions | 3Q 2021 | 3Q 2020 | YTD 2021 | YTD 2020 | ||||||||||||
Premium income | ||||||||||||||||
Life insurance | 3,196 | 3,120 | 9,964 | 10,646 | ||||||||||||
Non-life insurance | 466 | 490 | 1,565 | 1,708 | ||||||||||||
Total premium income | 3,662 | 3,610 | 11,529 | 12,354 | ||||||||||||
Accident and health insurance | 364 | 394 | 1,263 | 1,416 | ||||||||||||
Property & casualty insurance | 101 | 97 | 301 | 292 | ||||||||||||
Non-life Insurance premium income | 466 | 490 | 1,565 | 1,708 | ||||||||||||
Premiums paid to reinsurers 1 | ||||||||||||||||
Life insurance | 510 | 523 | 1,574 | 1,638 | ||||||||||||
Non-life insurance | 50 | 39 | 143 | 126 | ||||||||||||
Total premiums paid to reinsurers | 559 | 563 | 1,718 | 1,763 | ||||||||||||
Accident and health insurance | 43 | 33 | 123 | 106 | ||||||||||||
Property & casualty insurance | 7 | 6 | 20 | 19 | ||||||||||||
Non-life Insurance paid to reinsurers | 50 | 39 | 143 | 126 |
1 Premiums paid to reinsurers are recorded within Benefits and expenses in the income statement - refer to note Benefits and expenses.
Premium income in the first nine months of 2021 decreased, compared to the first nine months of 2020, mainly driven by the reduction of the Individual Life portfolio in NL, reduction of upgraded Life insurance policies to the retirement platform in the UK, and reduced new business related to COVID-19.
5. Investment income
EUR millions | 3Q 2021 | 3Q 2020 | YTD 2021 | YTD 2020 | ||||||||||||
Interest income | 1,309 | 1,311 | 3,908 | 4,116 | ||||||||||||
Dividend income | 106 | 156 | 1,192 | 1,321 | ||||||||||||
Rental income | 25 | 31 | 74 | 95 | ||||||||||||
Total investment income | 1,440 | 1,498 | 5,174 | 5,532 | ||||||||||||
Investment income related to general account | 1,228 | 1,224 | 3,617 | 3,815 | ||||||||||||
Investment income for account of policyholders | 212 | 274 | 1,557 | 1,717 | ||||||||||||
Total | 1,440 | 1,498 | 5,174 | 5,532 |
Unaudited
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
6. Results from financial transactions
EUR millions | 3Q 2021 | 3Q 2020 | YTD 2021 | YTD 2020 | ||||||||||||
Net fair value change of general account financial investments at FVTPL other than derivatives | 268 | 124 | 636 | (94) | ||||||||||||
Realized gains /(losses) on financial investments | 134 | 56 | 343 | 53 | ||||||||||||
Gains /(losses) on investments in real estate | 70 | 23 | 110 | 34 | ||||||||||||
Net fair value change of derivatives | (355) | 69 | (1,920) | (58) | ||||||||||||
Net fair value change on for account of policyholder financial assets at FVTPL | 841 | 7,354 | 14,837 | 3,059 | ||||||||||||
Net fair value change on investments in real estate for account of policyholders | 15 | (5) | 24 | (41) | ||||||||||||
Net foreign currency gains /(losses) | 39 | (13) | 162 | (35) | ||||||||||||
Net fair value change on borrowings and other financial liabilities | - | 6 | - | 11 | ||||||||||||
Total | 1,012 | 7,614 | 14,193 | 2,929 |
Net fair value change on for account of policyholder financial assets at fair value through profit or loss decreased in 3Q 2021 compared to 3Q 2020, mainly from less favorable equity markets. On a year-to-date basis, the result increased driven by the impact of positive equity markets and as 2020 was significantly impacted by COVID-19. Net fair value changes on for account of policyholder financial assets at fair value through profit or loss are offset by changes in technical provisions reported as part of the lines “Change in valuation of liabilities for insurance contracts” and “Change in valuation of liabilities for investment contracts” in note 7 Benefits and expenses.
7 Benefits and expenses
EUR millions | 3Q 2021 | 3Q 2020 | YTD 2021 | YTD 2020 | ||||||||||||
Claims and benefits | 6,593 | 13,823 | 31,068 | 22,549 | ||||||||||||
Employee expenses | 506 | 484 | 1,473 | 1,522 | ||||||||||||
Administration expenses | 377 | 385 | 1,164 | 1,207 | ||||||||||||
Deferred expenses | (182) | (177) | (487) | (577) | ||||||||||||
Amortization charges | 583 | 198 | 927 | 712 | ||||||||||||
Total | 7,876 | 14,713 | 34,145 | 25,412 | ||||||||||||
Benefits and claims paid life | 4,199 | 4,432 | 14,827 | 10,678 | ||||||||||||
Benefits and claims paid non-life | 361 | 355 | 1,053 | 1,134 | ||||||||||||
Change in valuation of liabilities for insurance contracts | 741 | 7,480 | 9,557 | 8,945 | ||||||||||||
Change in valuation of liabilities for investment contracts | 155 | 429 | 2,227 | (1,705) | ||||||||||||
Other | (4) | (2) | (27) | 3 | ||||||||||||
Policyholder claims and benefits | 5,453 | 12,694 | 27,637 | 19,056 | ||||||||||||
Premium paid to reinsurers | 559 | 563 | 1,718 | 1,763 | ||||||||||||
Profit sharing and rebates | 2 | 4 | 6 | 8 | ||||||||||||
Commissions | 579 | 562 | 1,707 | 1,721 | ||||||||||||
Total | 6,593 | 13,823 | 31,068 | 22,549 |
Aegon expanded the dynamic hedge covering the equity and interest rate risks of its US Variable Annuities block with guaranteed minimum withdrawal benefits (GMWB) to the entire VA portfolio. Implementing the VA dynamic hedging program for variable annuities with interest sensitive guaranteed minimum income benefits (GMIBs) and guaranteed minimum death benefits (GMDBs) resulted in a EUR 350 million onetime charge as included in “Amortization charges” and EUR 11 million one-time charge as included in “Policyholder claims and benefits”. In addition, Aegon launched a lump-sum buy-out program in July 2021 for policyholders of variable annuities with GMIB riders whose financial objectives may have changed since the issuance of their policies. The execution of the lump-sum buy-out program resulted in a charge of EUR 109 million as recorded in “Policyholder claims and benefits”, to record actual and expected offer acceptances.
The lines “Change in valuation of liabilities for insurance contracts” and “Change in valuation of liabilities for investment contracts” reflect changes in technical provisions resulting from “Net fair value changes on for account of policyholder financial assets at fair value through profit or loss” included in note 6 Results from financial transactions. In addition, the line “Change in valuation of liabilities for insurance contracts” includes the movement of the technical provisions for life insurance contracts.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
8. Other charges
Other charges in the first nine months of 2021 are mainly due to the settlements of litigation related to monthly deduction rate adjustments on certain universal life policies, for more details refer to Note 19 commitments and contingencies.
9. Income tax
The income tax benefit includes recurring beneficial impacts of tax exempt income and US tax credits. Tax exempt income is comprised of the regular non-taxable items such as the dividend received deduction in the US and the participation exemption in the Netherlands. Tax credits mainly include tax benefits from US investments that provide affordable housing to individuals and families that meet median household income requirements.
10. Investments
| ||||||||
EUR millions | September 30, 2021 | December 31, 2020 | ||||||
Available-for-sale (AFS) | 101,576 | 99,580 | ||||||
Loans | 46,972 | 45,573 | ||||||
Financial assets at fair value through profit or loss (FVTPL) | 7,471 | 10,057 | ||||||
Financial assets, for general account, excluding derivatives | 156,019 | 155,210 | ||||||
Investments in real estate | 2,500 | 2,385 | ||||||
Total investments for general account, excluding derivatives | 158,519 | 157,595 |
Financial assets, for general account, excluding derivatives
| ||||||||||||||||
EUR millions | AFS | FVTPL | Loans | Total | ||||||||||||
Shares | 349 | 1,572 | - | 1,920 | ||||||||||||
Debt securities | 94,806 | 2,609 | - | 97,415 | ||||||||||||
Money market and other short-term investments | 5,483 | 131 | - | 5,613 | ||||||||||||
Mortgages loans | - | - | 40,578 | 40,578 | ||||||||||||
Private loans | - | - | 4,435 | 4,435 | ||||||||||||
Deposits with financial institutions | - | - | 82 | 82 | ||||||||||||
Policy loans | - | - | 1,866 | 1,866 | ||||||||||||
Other | 939 | 3,159 | 10 | 4,108 | ||||||||||||
September 30, 2021 | 101,576 | 7,471 | 46,972 | 156,019 | ||||||||||||
AFS | FVTPL | Loans | Total | |||||||||||||
Shares | 345 | 1,634 | - | 1,979 | ||||||||||||
Debt securities | 93,681 | 5,669 | - | 99,350 | ||||||||||||
Money market and other short-term investments | 4,558 | 109 | - | 4,667 | ||||||||||||
Mortgages loans | - | - | 39,298 | 39,298 | ||||||||||||
Private loans | - | - | 4,358 | 4,358 | ||||||||||||
Deposits with financial institutions | - | - | 92 | 92 | ||||||||||||
Policy loans | - | - | 1,801 | 1,801 | ||||||||||||
Other | 996 | 2,645 | 25 | 3,665 | ||||||||||||
December 31, 2020 | 99,580 | 10,057 | 45,573 | 155,210 |
Total investments for general account in the first nine months of 2021 increased, compared to the end of 2020 position, mainly due to fair value increases on assets from recovery in equity markets in US, partially offset by fair value decreases on assets from higher interest rates in NL and the positive impact of foreign currency translations.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
11. Investments for account of policyholders
| ||||||||
EUR millions | September 30, 2021 | December 31, 2020 | ||||||
Shares | 27,963 | 25,288 | ||||||
Debt securities | 19,598 | 19,885 | ||||||
Money market and short-term investments | 1,473 | 1,051 | ||||||
Deposits with financial institutions | 3,817 | 4,185 | ||||||
Unconsolidated investment funds | 182,950 | 168,777 | ||||||
Other | 4,341 | 4,520 | ||||||
Total investments for account of policyholders at fair value through profit or loss, excluding derivatives | 240,142 | 223,705 | ||||||
Investment in real estate | 490 | 467 | ||||||
Total investments for account of policyholders | 240,632 | 224,172 |
Investments for account of policyholders in the first nine months of 2021 increased, compared to the end of 2020 position, mainly due to positive market movements in US and UK and the impact of foreign currency translations.
12. Investments in joint ventures and associates
During 3Q 2021, Aegon amended its agreement related to the investment in Mongeral Aegon and injected EUR 40 million in the undertaking. Following the amendment and capital injection, the investment required reclassification from Investments in associates to Investments in joint ventures as the level of influence was affected. The reclassification, reflecting the carrying amount of the investment, amounted to EUR 97 million.
13. Fair value
The following tables provide an analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:
Fair value hierarchy
| ||||||||||||||||||||||||||||||||
EUR millions | September 30, 2021 | December 31, 2020 | ||||||||||||||||||||||||||||||
Level I | Level II | Level III | Total | Level I | Level II | Level III | Total | |||||||||||||||||||||||||
Financial assets carried at fair value | ||||||||||||||||||||||||||||||||
Available-for-sale investments | ||||||||||||||||||||||||||||||||
Shares | 84 | 77 | 187 | 349 | 90 | 82 | 173 | 345 | ||||||||||||||||||||||||
Debt securities | 25,866 | 68,406 | 534 | 94,806 | 28,300 | 64,914 | 467 | 93,681 | ||||||||||||||||||||||||
Money markets and other short-term instruments | 787 | 4,695 | - | 5,483 | 832 | 3,726 | - | 4,558 | ||||||||||||||||||||||||
Other investments at fair value | - | 357 | 582 | 939 | - | 415 | 581 | 996 | ||||||||||||||||||||||||
Total Available-for-sale investments | 26,737 | 73,536 | 1,303 | 101,576 | 29,222 | 69,136 | 1,221 | 99,580 | ||||||||||||||||||||||||
Fair value through profit or loss | ||||||||||||||||||||||||||||||||
Shares | 82 | 224 | 1,265 | 1,572 | 80 | 226 | 1,329 | 1,634 | ||||||||||||||||||||||||
Debt securities | 105 | 2,394 | 110 | 2,609 | 168 | 5,260 | 242 | 5,669 | ||||||||||||||||||||||||
Money markets and other short-term instruments | 17 | 113 | - | 131 | 17 | 93 | - | 109 | ||||||||||||||||||||||||
Other investments at fair value | 1 | 386 | 2,772 | 3,159 | 1 | 470 | 2,174 | 2,645 | ||||||||||||||||||||||||
Investments for account of policyholders 1 | 125,172 | 114,030 | 941 | 240,142 | 118,057 | 104,635 | 1,012 | 223,705 | ||||||||||||||||||||||||
Derivatives | 157 | 11,295 | 5 | 11,456 | 34 | 13,930 | 22 | 13,986 | ||||||||||||||||||||||||
Total Fair value through profit or loss | 125,535 | 128,442 | 5,094 | 259,070 | 118,356 | 124,613 | 4,779 | 247,748 | ||||||||||||||||||||||||
Total financial assets at fair value | 152,272 | 201,977 | 6,397 | 360,646 | 147,578 | 193,750 | 6,000 | 347,327 | ||||||||||||||||||||||||
Financial liabilities carried at fair value | ||||||||||||||||||||||||||||||||
Investment contracts for account of policyholders 2 | - | 67,175 | 1 | 67,176 | - | 59,637 | (12) | 59,625 | ||||||||||||||||||||||||
Derivatives | 45 | 10,261 | 3,607 | 13,913 | 61 | 9,654 | 4,902 | 14,617 | ||||||||||||||||||||||||
Total financial liabilities at fair value | 45 | 77,436 | 3,608 | 81,089 | 61 | 69,291 | 4,890 | 74,242 |
1 The investments for account of policyholders included in the table above represents only those investments carried at fair value through profit or loss.
2 The investment contracts for account of policyholders included in the table above represents only those investment contracts carried at fair value.
3 Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Significant transfers between Level I, Level II and Level III
The table below shows transfers between Level I and Level II for financial assets and financial liabilities recorded at fair value on a recurring basis.
Fair value transfers
| ||||||||||||||||
EUR millions | September 30, 2021 | December 31, 2020 | ||||||||||||||
Transfers Level I to Level II | Transfers Level II to Level I | Transfers Level I to Level II | Transfers Level II to Level I | |||||||||||||
Financial assets carried at fair value | ||||||||||||||||
Debt securities | 44 | 19 | - | 46 | ||||||||||||
Total | 44 | 19 | - | 46 | ||||||||||||
Fair value through profit or loss | ||||||||||||||||
Shares | - | - | - | - | ||||||||||||
Total | - | - | - | - | ||||||||||||
Total financial assets at fair value | 44 | 19 | - | 46 |
Transfers are identified based on transaction volume and frequency, which are indicative of an active market.
Movements in Level III financial instruments measured at fair value
The following table summarizes the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs (‘Level III’), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.
Roll forward of Level III financial instruments
|
| |||||||||||||||||||||||||||||||||||||||||||||||
EUR millions | January 1, 2021 | Acquisitions through business combinations | Total gains / | Total gains / losses in OCI 2 | Purchases | Sales | Settlements | Net exchange differences | Transfers from Level I and Level II | Transfers to Level I and Level II | September 30, 2021 | Total unrealized gains and losses for the period recorded in the P&L for instruments held at September 30, 2021 3 | ||||||||||||||||||||||||||||||||||||
Financial assets carried at fair value | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares | 173 | - | 6 | (2 | ) | 39 | (36 | ) | - | 8 | - | - | 187 | - | ||||||||||||||||||||||||||||||||||
Debt securities | 467 | - | (2 | ) | 11 | 159 | (21 | ) | (40 | ) | 16 | 192 | (249 | ) | 534 | - | ||||||||||||||||||||||||||||||||
Other investments at fair value | 581 | - | (89 | ) | 8 | 68 | (13 | ) | (4 | ) | 31 | - | - | 582 | - | |||||||||||||||||||||||||||||||||
1,221 | - | (85 | ) | 17 | 266 | (71 | ) | (45 | ) | 56 | 192 | (249 | ) | 1,303 | - | |||||||||||||||||||||||||||||||||
Fair value through profit or loss | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares | 1,329 | - | 103 | - | 32 | (200 | ) | 1 | 1 | - | - | 1,265 | 99 | |||||||||||||||||||||||||||||||||||
Debt securities | 242 | - | - | - | 108 | (239 | ) | - | - | - | - | 110 | 1 | |||||||||||||||||||||||||||||||||||
Other investments at fair value | 2,173 | - | 600 | - | 340 | (473 | ) | - | 132 | - | - | 2,772 | 1 | |||||||||||||||||||||||||||||||||||
Investments for account of policyholders | 1,012 | - | 139 | - | 88 | (306 | ) | - | 14 | - | (7 | ) | 941 | (59 | ) | |||||||||||||||||||||||||||||||||
Derivatives | 22 | - | (17 | ) | - | - | - | - | - | - | - | 5 | (10 | ) | ||||||||||||||||||||||||||||||||||
4,779 | - | 824 | - | 569 | (1,218 | ) | - | 147 | - | (7 | ) | 5,094 | 33 | |||||||||||||||||||||||||||||||||||
Total assets at fair value | 6,000 | - | 739 | 17 | 835 | (1,288 | ) | (45 | ) | 203 | 192 | (256 | ) | 6,397 | 33 | |||||||||||||||||||||||||||||||||
Financial liabilities carried at fair value | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment contracts for account of policyholders | (12 | ) | - | (1 | ) | - | (195 | ) | 207 | - | 1 | - | - | 1 | 1 | |||||||||||||||||||||||||||||||||
Derivatives | 4,902 | - | (1,413 | ) | - | - | (11 | ) | - | 129 | - | - | 3,607 | 443 | ||||||||||||||||||||||||||||||||||
4,890 | - | (1,414 | ) | - | (195 | ) | 197 | - | 131 | - | - | 3,608 | 444 |
EUR millions | January 1, 2020 | Acquisitions through business combinations | Total gains / | Total gains / losses in OCI 2 | Purchases | Sales | Settlements | Net exchange differences | Transfers from Level I and Level II | Transfers to Level I and Level II | December 31, 2020 | Total unrealized gains and losses for the period recorded in the P&L for instruments held at December 31, 2020 ³ | ||||||||||||||||||||||||||||||||||||
Financial assets carried at fair value | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares | 157 | - | (27 | ) | 24 | �� | 49 | (15 | ) | (1 | ) | (12 | ) | - | (2 | ) | 173 | - | ||||||||||||||||||||||||||||||
Debt securities | 1,074 | - | 3 | (19 | ) | 155 | (11 | ) | (34 | ) | (32 | ) | 26 | (695 | ) | 467 | - | |||||||||||||||||||||||||||||||
Other investments at fair value | 482 | - | (140 | ) | 28 | 302 | (19 | ) | (22 | ) | (50 | ) | - | - | 581 | - | ||||||||||||||||||||||||||||||||
1,712 | - | (163 | ) | 34 | 505 | (45 | ) | (56 | ) | (94 | ) | 26 | (697 | ) | 1,221 | - | ||||||||||||||||||||||||||||||||
Fair value through profit or loss | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares | 1,401 | - | (132 | ) | - | 160 | (97 | ) | - | (3 | ) | - | - | 1,329 | (98 | ) | ||||||||||||||||||||||||||||||||
Debt securities | 4 | - | - | - | 276 | (37 | ) | - | - | - | - | 242 | - | |||||||||||||||||||||||||||||||||||
Other investments at fair value | 2,049 | - | 122 | - | 432 | (250 | ) | - | (184 | ) | 16 | (13 | ) | 2,173 | (1 | ) | ||||||||||||||||||||||||||||||||
Investments for account of policyholders | 1,805 | - | 3 | - | (168 | ) | (607 | ) | - | (20 | ) | - | - | 1,012 | 37 | |||||||||||||||||||||||||||||||||
Derivatives | 56 | - | (33 | ) | - | - | - | - | - | - | - | 22 | (32 | ) | ||||||||||||||||||||||||||||||||||
5,314 | - | (40 | ) | - | 700 | (991 | ) | - | (207 | ) | 16 | (13 | ) | 4,779 | (93 | ) | ||||||||||||||||||||||||||||||||
Total assets at fair value | 7,026 | - | (203 | ) | 33 | 1,205 | (1,037 | ) | (57 | ) | (301 | ) | 42 | (710 | ) | 6,000 | (93 | ) | ||||||||||||||||||||||||||||||
Financial liabilities carried at fair value | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment contracts for account of policyholders | 197 | - | 9 | - | (200 | ) | (16 | ) | - | (3 | ) | - | - | (12 | ) | 7 | ||||||||||||||||||||||||||||||||
Derivatives | 3,081 | - | 2,073 | (9 | ) | - | (15 | ) | - | (228 | ) | - | - | 4,902 | 314 | |||||||||||||||||||||||||||||||||
3,278 | - | 2,082 | (9 | ) | (200 | ) | (31 | ) | - | (231 | ) | - | - | 4,890 | 321 |
1 Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item results from financial transactions of the income statement.
2 Total gains and losses are recorded in line items gains/ (losses) on revaluation of available-for-sale investments and (gains)/ losses transferred to the income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive income.
3 Total gains / (losses) for the period during which the financial instrument was in Level III.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Fair value information about financial instruments not measured at fair value
The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at fair value on a recurring basis.
Fair value information about financial instruments not measured at fair value
| ||||||||||||||||
Carrying amount | Total estimated fair value | Carrying amount | Total estimated fair value | |||||||||||||
EUR millions | September 30, 2021 | December 31, 2020 | ||||||||||||||
Assets | ||||||||||||||||
Mortgage loans - held at amortized cost | 40,578 | 44,733 | 39,298 | 43,258 | ||||||||||||
Private loans - held at amortized cost | 4,435 | 5,100 | 4,358 | 5,280 | ||||||||||||
Other loans - held at amortized cost | 1,958 | 1,958 | 1,917 | 1,917 | ||||||||||||
Liabilities | ||||||||||||||||
Subordinated borrowings - held at amortized cost | 2,165 | 2,426 | 2,085 | 2,351 | ||||||||||||
Trust pass-through securities - held at amortized cost | 126 | 139 | 126 | 142 | ||||||||||||
Borrowings – held at amortized cost | 9,464 | 9,841 | 8,524 | 9,165 | ||||||||||||
Investment contracts - held at amortized cost | 21,557 | 20,913 | 20,889 | 20,382 |
Financial instruments for which carrying value approximates fair value
Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.
14. Share capital
EUR millions | September 30, 2021 | December 31, 2020 | ||||||||||||||
Share capital - par value | 321 | 320 | ||||||||||||||
Share premium | 7,033 | 7,160 | ||||||||||||||
Total share capital | 7,354 | 7,480 | ||||||||||||||
Share capital - par value | ||||||||||||||||
Balance at January 1 | 320 | 323 | ||||||||||||||
Dividend | 1 | - | ||||||||||||||
Shares withdrawn | - | (3 | ) | |||||||||||||
Balance | 321 | 320 | ||||||||||||||
Share premium | ||||||||||||||||
Balance at January 1 | 7,160 | 7,213 | ||||||||||||||
Share dividend | (127 | ) | (54 | ) | ||||||||||||
Balance | 7,033 | 7,160 | ||||||||||||||
3Q | 3Q | YTD | YTD | |||||||||||||
EUR millions | 2021 | 2020 | 2021 | 2020 | ||||||||||||
Earnings per share (EUR per share) | ||||||||||||||||
Basic earnings per common share | (0.04 | ) | (0.20 | ) | 0.54 | (0.12 | ) | |||||||||
Basic earnings per common share B | - | (0.01 | ) | 0.01 | - | |||||||||||
Diluted earnings per common share | (0.04 | ) | (0.20 | ) | 0.54 | (0.12 | ) | |||||||||
Diluted earnings per common share B | - | (0.01 | ) | 0.01 | - | |||||||||||
Earnings per share calculation | ||||||||||||||||
Net result attributable to owners of Aegon N.V. | (79 | ) | (419 | ) | 1,147 | (217 | ) | |||||||||
Coupons on other equity instruments | (2 | ) | 5 | (26 | ) | (24 | ) | |||||||||
Earnings attributable to common shares and common shares B | (81 | ) | (414 | ) | 1,121 | (241 | ) | |||||||||
Earnings attributable to common shareholders | (81 | ) | (411 | ) | 1,114 | (239 | ) | |||||||||
Earnings attributable to common shareholders B | (1 | ) | (3 | ) | 8 | (2 | ) | |||||||||
Weighted average number of common shares outstanding (in millions) | 2,046 | 2,047 | 2,045 | 2,042 | ||||||||||||
Weighted average number of common shares B outstanding (in millions) | 561 | 562 | 560 | 561 |
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Final dividend 2020
It was decided at the Annual General Meeting of Shareholders on June 3, 2021 to pay a final dividend for 2020 of EUR 0.06 per common share and EUR 0.0015 per common share B. After taking into account the interim dividend of EUR 0.06 per common share and EUR 0.0015 per common share B, this resulted in a total 2020 dividend of EUR 0.12 per common share and EUR 0.0030 per common share B.
The final dividend for 2020 was paid in cash or stock at the election of the shareholder. The value of the dividend in common shares was approximately equal to the cash dividend. Those who elected to receive a stock dividend received one Aegon common share for every 59 common shares held. The stock fraction was based on Aegon’s average share price as quoted on Euronext Amsterdam, using the high and low of each of the five trading days from June 24 up to and including June 30, 2021. The average price calculated on this basis amounted to EUR 3.52. The dividend was paid as of July 7, 2021.
2021 interim dividend
Aegon paid an interim dividend for 2021 of EUR 0.08 per common share. The interim dividend for 2021 was paid in cash or stock at the election of the shareholder. The value of the dividend in common shares was approximately equal to the cash dividend. Those who elected to receive a stock dividend received one Aegon common share for every 52 common shares held. The stock fraction was based on the average share price on Euronext Amsterdam, using the high and low of each of the five trading days from September 6 through September 10, 2021. The average price calculated on this basis amounted to EUR 4.15. The dividend was paid as of September 17, 2021.
Share buyback
During 3Q 2021, Aegon completed the share buyback program to neutralize the dilutive effect of the 2020 final dividend paid in shares and certain share-based variable compensation plans for senior management. The repurchased shares will be held as treasury shares and will either be used to cover future dividends to be paid in shares, or will be allocated to the participants of share-based variable compensation plans. Between July 8, 2021 and August 20, 2021 a total of 35,933,035 common shares were repurchased, at an average price of EUR 3.7013 per share.
On September 17, 2021, Aegon announced that it will repurchase common shares for an amount of EUR 96 million to neutralize the dilutive effect of its 2021 interim dividend paid in shares. These shares will be held as treasury shares and will be used to pay future dividends in shares. Shareholders were given the opportunity to choose between receiving the 2021 interim dividend of EUR 0.08 per common share in cash or in shares. 58% of shareholders elected to receive the interim dividend in shares. The repurchase will commence on October 1, 2021 and was completed before October 27, 2021. Between October 1, 2021 and October 26, 2021 a total of 21,531,927 common shares were repurchased, at an average price of EUR 4.46 per share.
15. Other equity instruments
With effect on September 15, 2021, Aegon has exercised its right to redeem USD 250 million floating rate perpetual capital securities with a minimum coupon of 4% issued in 2005. The securities had no stated maturity, however Aegon had the right to call the securities for redemption.
16. Borrowings
EUR millions | September 30, 2021 | December 31, 2020 | ||
Capital funding | 1,274 | 1,241 | ||
Operational funding | 8,191 | 7,283 | ||
Total borrowings | 9,464 | 8,524 |
During 3Q 2021, the operational funding increased by EUR 0.9 billion due to an increase in Federal Home Loan Bank advances of EUR
0.5 billion and an increase of mortgage loan funding of EUR 0.4 billion.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
17. Financial risks
There have been no significant changes in sensitivities for equity market risk, bond credit spreads and liquidity premium per December 31, 2020 as reported in Aegon’s 2020 Integrated Annual Report. Aegon’s sensitivity to interest rate risk has changed per September 30, 2021. This is the net result of the effect of the implementation of an interest rate macro hedge in the United States and the effect from the improvement of the LAT deficit in the Netherlands.
The table below shows the updated sensitivity per September 30, 2021 of the effect of a parallel shift in the yield curves on net result and shareholders’ equity.
EUR millions | September 30, 2021 | December 31, 2020 | ||||||||||
| Estimated approximate effects on net result | | Estimated approximate effects on shareholders’ equity | | Estimated approximate effects on net result | | Estimated approximate effects on shareholders’ equity | |||||
Parallel movements of yield curve | ||||||||||||
Immediate movements of yield curve, but not permanently | ||||||||||||
Shift up 100 basis points | (366 | ) | (4,112) | 187 | (2,316) | |||||||
Shift down 100 basis points | 243 | 3,332 | (462 | ) | 2,064 |
18. Capital management and solvency
As at September 30, 2021, Aegon’s estimated capital position was:
Solvency II key figures | ||||||
September 30, 20211 | December 31, 2020 | |||||
EUR millions | ||||||
Group Own Funds | 19,192 | 18,582 | ||||
Group SCR | 9,189 | 9,473 | ||||
Group Solvency II ratio | 209% | 196% |
1 The Solvency II ratios are estimates, are not final until filed with the respective supervisory authority.
The table below provides the composition of Aegon’s Available Own Funds across Tiers:
Available Own Funds | ||||||
September 30, 2021 | December 31, 2020 | |||||
EUR millions | ||||||
Tier 1 - unrestricted | 13,798 | 12,971 | ||||
Tier 1 - restricted | 2,373 | 2,571 | ||||
Tier 2 | 2,344 | 2,340 | ||||
Tier 3 | 677 | 700 | ||||
Total Available Own Funds | 19,192 | 18,582 |
The table below provides the reconciliation from shareholders’ equity to Solvency II Own Funds:
Reconciliation Shareholders’ Equity - Own Funds
| ||||||
September 30, 2021 | December 31, 2020 | |||||
EUR millions | ||||||
IFRS Shareholders’ Equity | 23,603 | 22,815 | ||||
IFRS adjustments for Other Equity instruments and non controlling interests | 2,529 | 2,644 | ||||
IFRS Group Equity | 26,132 | 25,459 | ||||
Solvency II revaluations and reclassifications | (9,443 | ) | (9,418) | |||
Transferability restrictions 1 | (1,718 | ) | (1,766) | |||
Excess of Assets over Liabilities | 14,971 | 14,274 | ||||
Availability adjustments | 4,315 | 4,416 | ||||
Fungibility adjustments | (93 | ) | (108) | |||
Available Own Funds | 19,192 | 18,582 |
1 This includes the transferability restriction related to the RBC CAL conversion methodology.
The Solvency II revaluations and reclassifications mainly stem from the difference in valuation and presentation between IFRS-EU and Solvency II frameworks.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
19. Commitments and contingencies
Several US insurers, including Aegon subsidiaries, have been named in class actions as well as individual litigation relating to increases in monthly deduction rates (‘’MDR’’) on universal life products. Plaintiffs generally allege that the increases were made to recoup past losses rather than to cover the future costs of providing insurance coverage. Aegon’s subsidiary in the US has agreed to settle two such class actions that had been venued in the US District Court for the Central District of California. The settlement in the first case, approved in January 2019, arose from increases implemented in 2015-2016. Over 99% of affected policyholders participated in that settlement. While less than 1% of policyholders opted out of the settlement, they represented approximately 43% of the value of the settlement fund. In 2021, settlements have been reached with some of these opt out parties. In the second case, Aegon’s subsidiary agreed to settle a class action lawsuit arising out of MDR increases in 2017 and 2018. The court approved that settlement on September 16, 2020. Opt-outs in this case represent less than 7% of the value of the settlement fund. On October 15, 2020, two opt-out policyholders whose objections to the settlement were overruled by the trial court filed an appeal, which delayed implementation of the settlement. Aegon’s subsidiary expects settlement implementation to begin shortly. The remaining opt-out cases and disputes are ongoing, and Aegon continues to hold a provision for the remaining opt-outs from the settlements that were approved by the court in 2019 and 2020. If this provision for these cases proves to be insufficient, then these cases could have an adverse effect on Aegon’s business, results of operations, and financial position.
20. Acquisitions/Divestments
On February 28, 2021, Aegon completed the divestment of Stonebridge, a UK-based provider of accident insurance products to Global Premium Holdings group, part of Embignell group. Under the terms of the agreement, Aegon sold Stonebridge for a consideration of approximately GBP 60 million, consisting of the purchase price and dividends related to the transaction. This excludes a contingent consideration of up to GBP 10 million. The transaction had no material impact on Aegon’s capital position and results.
On November 29, 2020, Aegon agreed to sell its insurance, pension, and asset management businesses in Hungary, Poland, Romania, and Turkey to Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG) for EUR 830 million. The European Commission granted competition law clearance for the acquisition on August 12, 2021. However, the decision by the Hungarian Ministry of the Interior dated April 6, 2021 to block VIG’s acquisition of Aegon’s Hungarian subsidiaries remains in place. On September 20, 2021, the Budapest Metropolitan Court rejected VIG’s and Aegon’s joint appeal challenging this decision. Subsequently, VIG and Aegon requested the Hungarian Supreme Court to review the ruling of the Budapest Metropolitan Court on October 19, 2021. Next to that, the European Commission announced on October 29, 2021 to open an investigation to assess whether the decision by Hungary to veto the acquisition of Aegon’s Hungarian subsidiaries by VIG constitutes a breach of the European Union Merger Regulation. Irrespective of these developments, VIG is continuing its constructive dialogue with the Hungarian Ministry of Finance to clarify possibilities for a positive conclusion of the acquisition.
21. Post reporting date events
On October 27, 2021, Aegon announced that it completed the share buyback program to neutralize the dilutive effect of the 2021 interim dividend paid in shares, for more details refer to note 14 Share Capital.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Disclaimers
Cautionary note regarding non-IFRS-EU measures
This document includes the following non-IFRS-EU financial measures: operating result, income tax and result before tax. These non-IFRS-EU measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. The reconciliation of these measures to the most comparable IFRS-EU measure is provided in note 3 ‘Segment information’ of Aegon’s Condensed Consolidated Interim Financial Statements. Aegon believes that these non-IFRS-EU measures, together with the IFRS-EU information, provide meaningful supplemental information about the operating results of Aegon’s business including insight into the financial measures that senior management uses in managing the business.
Forward-looking statements
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:
¨ | Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom; |
¨ | Changes in the performance of financial markets, including emerging markets, such as with regard to: |
- | The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; |
- | The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and |
- | The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds; |
¨ | Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties; |
¨ | Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition; |
¨ | Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries; |
¨ | The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain; |
¨ | Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; |
¨ | Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; |
¨ | Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness; |
¨ | Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets; |
¨ | Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business; |
¨ | The frequency and severity of insured loss events; |
¨ | Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products; |
¨ | Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results; |
¨ | Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations; |
¨ | Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations; |
¨ | Customer responsiveness to both new products and distribution channels; |
¨ | As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows; |
¨ | The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions; |
¨ | Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management initiatives related to cost savings, cash capital at Holding, gross financial leverage and free cash flow; |
¨ | Changes in the policies of central banks and/or governments; |
¨ | Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business; |
¨ | Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products; |
¨ | Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union; |
¨ | Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers; |
¨ | Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates; |
¨ | Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and |
¨ | Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels. |
This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Unaudited
|
| ![]() |
Table of Contents
Condensed consolidated interim financial statements for the periods ended September 30, 2021
Corporate and shareholder information
Headquarters
Aegon N.V.
P.O. Box 85
2501 CB The Hague
The Netherlands
+ 31 (0) 70 344 32 10
aegon.com
Group Corporate Communications & Investor Relations
Media relations
+ 31 (0) 70 344 8344
gcc@aegon.com
Investor relations
+ 31 (0) 70 344 83 05
or 877 548 96 68 - toll free, USA only
ir@aegon.com
Publication dates results
February 9, 2022 | 4Q 2021 Results | |
May 12, 2022 | 1Q 2022 Results |
About Aegon
Aegon’s roots go back more than 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in the Americas, Europe, and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions, and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information: aegon.com.
Unaudited
|
| ![]() |